Chronic low‑level nociceptive signaling may act as a hormetic stimulus that preserves mitochondrial function and extends healthspan. We hypothesize that basal activity of sensory neurons releasing substance P and CGRP tonically activates AMPK‑SIRT1‑PGC1α pathways, thereby promoting mitochondrial biogenesis, autophagy, and antioxidant defenses. Pharmacological silencing of these pathways with chronic analgesics removes this tonic signal, leading to progressive mitochondrial decline and accelerated cellular aging.

Mechanistic Rationale

Nociceptors convey more than pain; they release neuropeptides that modulate cellular stress responses. Substance P can activate NK1 receptors on non‑neuronal cells, triggering calcium fluxes that stimulate CaMKKβ‑AMPK signaling. CGRP similarly elevates cAMP, which can cross‑talk with AMPK via PKA‑dependent phosphorylation of LKB1. Both pathways converge on SIRT1 activation, enhancing deacetylation of PGC1α and driving mitochondrial gene expression. This creates a feedback loop where mild oxidative stress from neuronal activity upregulates endogenous antioxidant enzymes (SOD2, catalase) and mitophagy (via PINK1/Parkin). When analgesics blunt substance P/CGRP release, AMPK‑SIRT1 signaling falls, reducing PGC1α activity, lowering mitochondrial copy number, and increasing ROS‑induced damage.

Testable Predictions

1. Mice subjected to lifelong low‑dose NSAID or acetaminophen treatment will show reduced lifespan and earlier onset of age‑related pathologies compared with vehicle controls, despite equivalent pain scores.
2. Genetic ablation of substance P (Tac1‑/‑) or CGRP (Calca‑/‑) neurons in adult mice will recapitulate the mitochondrial deficits and shortened lifespan seen with pharmacological analgesia.
3. Optogenetic activation of TRPV1‑positive nociceptors for 30 min daily will extend median lifespan and improve grip strength, glucose tolerance, and markers of mitochondrial respiration in wild‑type mice.
4. Treating analgesic‑exposed mice with an AMPK activator (e.g., AICAR) or SIRT1 agonist (e.g., SRT1720) will rescue mitochondrial mass and normalize survival curves.

Experimental Design

Cohort setup: Use C57BL/6J mice, split into four groups (n=150 per sex): vehicle, chronic ibuprofen (50 mg/kg/day), chronic acetaminophen (150 mg/kg/day), and combined treatment. Administer via drinking water from 8 weeks of age until natural death. Monitor pain thresholds weekly with von Frey filaments to ensure analgesia without complete nocptive blockade. Outcomes: Survival analysis, frailty index, MRI‑based mitochondrial density in muscle and brain, Seahorse respirometry on isolated fibroblasts, LC‑MS/MS quantification of NAD+/NADH, acetyl‑p53, and PGC1α levels. Include histologic scoring for fibrosis and lipofuscin accumulation. Intervention arms: In a parallel experiment, Tac1‑/‑ and Calca‑/‑ mice receive either vehicle or daily optogenetic stimulation (473 nm, 10 Hz, 5 ms pulses) targeting dorsal root ganglia. Compare to wild‑type stimulated and non‑stimulated controls. Rescue test: Subset of ibuprofen‑treated mice receive AICAR (250 mg/kg i.p., 3×/week) or SRT1720 (100 mg/kg oral daily) starting at 6 months; assess whether longevity deficits are ameliorated.

If the data show that reducing nociceptive tone shortens lifespan and that boosting downstream AMPK‑SIRT1 signaling rescues this effect, the hypothesis gains strong support. Conversely, no lifespan difference between analgesic‑treated and control animals would falsify the notion that basal pain signaling is a longevity‑promoting hormetic cue. This approach directly links sensory physiology to mitochondrial aging, offering a mechanistic bridge between the hormesis literature and analgesic epidemiology.